Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Biochemical Society Transactions|August 12, 2014
Intrinsic and acquired resistance to MEK1/2 inhibitors in cancerMatthew J Sale, Simon J Cook
The Biochemical Journal|December 14, 2012
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistanceMatthew J Sale, Simon J Cook
The Biochemical Journal|February 18, 2014
The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stabilityMatthew J Sale, Simon J Cook
British Journal of Pharmacology|May 8, 2013
That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistanceMatthew J Sale, Simon J Cook
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addictionMatthew J Sale, Kathryn Balmanno, Simon J Cook
The FEBS Journal|May 27, 2017
Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signallingSimon J Cook, Kate Stuart, Rebecca Gilley, et al.
Nature Reviews. Cancer|September 25, 2015
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding roadChristopher J Caunt, Matthew J Sale, Paul D Smith, et al.
Biochemical Society Transactions|January 21, 2012
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodellingAnnette S Little, Kathryn Balmanno, Matthew J Sale, et al.
The Biochemical Journal|April 5, 2023
ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1Kathryn Balmanno, Andrew M Kidger, Dominic P Byrne, et al.
Molecular Cell|August 16, 2014
Lysine acetylation controls local protein conformation by influencing proline isomerizationFrançoise S Howe, Ivan Boubriak, Matthew J Sale, et al.
Pageof 3